| Website | thirdrockventures... |
| Phone | (617) 585-2000 |
| Employees | |
| Founded | 2007 |
| Fund II, 9/10 | $426M |
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace.
| Company | Date | Round | Size | Participants |
| Warp Drive Bio | 1/12 | Unattributed | $125M | 3 |
| Ember Therapeutics | 12/11 | Series A | $34M | 1 |
| Agios Pharmaceuticals | 11/11 | Series C | $78M | 4 |
| Allena Pharmaceuticals | 11/11 | Series A | $15M | 3 |
| Topica Pharmaceuticals | 10/11 | Series B | $27M | 3 |
| SAGE Therapeutics | 10/11 | Series A | $35M | 1 |
| Foundation Medicine | 10/11 | Series A | $33.5M | 3 |
| Zafgen | 7/11 | Series C | $33M | 2 |
| Lotus Tissue Repair | 6/11 | Series A | $26M | 1 |
| Constellation Pharmaceuticals | 6/11 | Series B | $15M | 5 |
| Seventh Sense Biosystems | 5/11 | Series A | $4.5M | 3 |
| bluebird bio | 4/11 | Unattributed | $30M | 5 |
| TARIS Biomedical | 4/11 | Series B | $18.3M | 4 |
| Blueprint Medicines | 4/11 | Series A | $40M | 1 |
| PanOptica | 1/11 | Series A | $30M | 2 |
| NinePoint Medical | 10/10 | Series A | $33M | 2 |
| CytomX Therapeutics | 9/10 | Series B | $30M | 2 |
| Constellation Pharmaceuticals | 6/10 | Series B | $4.8M | 5 |
| Ablexis | 6/10 | Series A | $12M | 2 |
| Zafgen | 3/10 | Series B | $28M | 3 |
| bluebird bio | 3/10 | Series B | $35M | 5 |
| Eleven Biotherapeutics | 3/10 | Series A | $35M | 2 |
| Afferent Pharmaceuticals | 12/09 | Series A | $23M | 4 |
| Constellation Pharmaceuticals | 8/09 | Series B | $17.2M | 4 |
| Alnara Pharmaceuticals | 10/08 | Series A | $20M | 3 |